Summary | |
---|---|
Symbol | AGER |
Name | advanced glycosylation end product-specific receptor |
Aliases | RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Isoform 1: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Secreted.; SUBCELLULAR LOCATION: Isoform 10: Cell membrane Single-pass type I membrane protein |
Domain |
PF08205 CD80-like C2-set immunoglobulin domain PF00047 Immunoglobulin domain PF13895 Immunoglobulin domain |
Function |
Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides. |
Biological Process |
GO:0001666 response to hypoxia GO:0001818 negative regulation of cytokine production GO:0001819 positive regulation of cytokine production GO:0001906 cell killing GO:0001909 leukocyte mediated cytotoxicity GO:0001910 regulation of leukocyte mediated cytotoxicity GO:0001913 T cell mediated cytotoxicity GO:0001914 regulation of T cell mediated cytotoxicity GO:0002246 wound healing involved in inflammatory response GO:0002248 connective tissue replacement involved in inflammatory response wound healing GO:0002250 adaptive immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002456 T cell mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002521 leukocyte differentiation GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002703 regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002709 regulation of T cell mediated immunity GO:0002819 regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0007159 leukocyte cell-cell adhesion GO:0007254 JNK cascade GO:0010001 glial cell differentiation GO:0010469 regulation of receptor activity GO:0014002 astrocyte development GO:0021782 glial cell development GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0031098 stress-activated protein kinase signaling cascade GO:0031341 regulation of cell killing GO:0031348 negative regulation of defense response GO:0032102 negative regulation of response to external stimulus GO:0032103 positive regulation of response to external stimulus GO:0032602 chemokine production GO:0032613 interleukin-10 production GO:0032615 interleukin-12 production GO:0032642 regulation of chemokine production GO:0032653 regulation of interleukin-10 production GO:0032655 regulation of interleukin-12 production GO:0032693 negative regulation of interleukin-10 production GO:0032722 positive regulation of chemokine production GO:0032735 positive regulation of interleukin-12 production GO:0032872 regulation of stress-activated MAPK cascade GO:0032874 positive regulation of stress-activated MAPK cascade GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0032946 positive regulation of mononuclear cell proliferation GO:0033674 positive regulation of kinase activity GO:0034103 regulation of tissue remodeling GO:0034104 negative regulation of tissue remodeling GO:0035710 CD4-positive, alpha-beta T cell activation GO:0036293 response to decreased oxygen levels GO:0040017 positive regulation of locomotion GO:0042063 gliogenesis GO:0042098 T cell proliferation GO:0042102 positive regulation of T cell proliferation GO:0042104 positive regulation of activated T cell proliferation GO:0042110 T cell activation GO:0042129 regulation of T cell proliferation GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0043506 regulation of JUN kinase activity GO:0043507 positive regulation of JUN kinase activity GO:0045785 positive regulation of cell adhesion GO:0045860 positive regulation of protein kinase activity GO:0046006 regulation of activated T cell proliferation GO:0046328 regulation of JNK cascade GO:0046330 positive regulation of JNK cascade GO:0046631 alpha-beta T cell activation GO:0046634 regulation of alpha-beta T cell activation GO:0046651 lymphocyte proliferation GO:0048708 astrocyte differentiation GO:0048771 tissue remodeling GO:0050670 regulation of lymphocyte proliferation GO:0050671 positive regulation of lymphocyte proliferation GO:0050727 regulation of inflammatory response GO:0050728 negative regulation of inflammatory response GO:0050798 activated T cell proliferation GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0050918 positive chemotaxis GO:0050920 regulation of chemotaxis GO:0050921 positive regulation of chemotaxis GO:0050926 regulation of positive chemotaxis GO:0050927 positive regulation of positive chemotaxis GO:0050930 induction of positive chemotaxis GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051092 positive regulation of NF-kappaB transcription factor activity GO:0051098 regulation of binding GO:0051101 regulation of DNA binding GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051403 stress-activated MAPK cascade GO:0061041 regulation of wound healing GO:0061045 negative regulation of wound healing GO:0070302 regulation of stress-activated protein kinase signaling cascade GO:0070304 positive regulation of stress-activated protein kinase signaling cascade GO:0070482 response to oxygen levels GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0071593 lymphocyte aggregation GO:0071605 monocyte chemotactic protein-1 production GO:0071637 regulation of monocyte chemotactic protein-1 production GO:0071639 positive regulation of monocyte chemotactic protein-1 production GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:0072657 protein localization to membrane GO:0090594 inflammatory response to wounding GO:0097028 dendritic cell differentiation GO:0097709 connective tissue replacement GO:1902105 regulation of leukocyte differentiation GO:1902107 positive regulation of leukocyte differentiation GO:1903034 regulation of response to wounding GO:1903035 negative regulation of response to wounding GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:1904596 regulation of connective tissue replacement involved in inflammatory response wound healing GO:1904597 negative regulation of connective tissue replacement involved in inflammatory response wound healing GO:1904603 regulation of advanced glycation end-product receptor activity GO:1904604 negative regulation of advanced glycation end-product receptor activity GO:1905203 regulation of connective tissue replacement GO:1905204 negative regulation of connective tissue replacement GO:2000272 negative regulation of receptor activity GO:2000514 regulation of CD4-positive, alpha-beta T cell activation GO:2001198 regulation of dendritic cell differentiation GO:2001200 positive regulation of dendritic cell differentiation |
Molecular Function |
GO:0005539 glycosaminoglycan binding GO:0008201 heparin binding GO:0044548 S100 protein binding GO:1901681 sulfur compound binding GO:1904599 advanced glycation end-product binding |
Cellular Component | - |
KEGG | - |
Reactome |
R-HSA-166054: Activated TLR4 signalling R-HSA-879415: Advanced glycosylation endproduct receptor signaling R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA R-HSA-3134963: DEx/H-box helicases activate type I IFN and inflammatory cytokines production R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-975871: MyD88 cascade initiated on plasma membrane R-HSA-975155: MyD88 dependent cascade initiated on endosome R-HSA-166166: MyD88-independent TLR3/TLR4 cascade R-HSA-166058: MyD88 R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways R-HSA-1810476: RIP-mediated NFkB activation via ZBP1 R-HSA-445989: TAK1 activates NFkB by phosphorylation and activation of IKKs complex R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines R-HSA-933542: TRAF6 mediated NF-kB activation R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade R-HSA-168179: Toll Like Receptor TLR1 R-HSA-168188: Toll Like Receptor TLR6 R-HSA-168898: Toll-Like Receptors Cascades R-HSA-1606322: ZBP1(DAI) mediated induction of type I IFNs |
Summary | |
---|---|
Symbol | AGER |
Name | advanced glycosylation end product-specific receptor |
Aliases | RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between AGER and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between AGER and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | AGER |
Name | advanced glycosylation end product-specific receptor |
Aliases | RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of AGER in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | AGER |
Name | advanced glycosylation end product-specific receptor |
Aliases | RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of AGER in various data sets.
|
Points in the above scatter plot represent the mutation difference of AGER in various data sets.
|
Summary | |
---|---|
Symbol | AGER |
Name | advanced glycosylation end product-specific receptor |
Aliases | RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AGER. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | AGER |
Name | advanced glycosylation end product-specific receptor |
Aliases | RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AGER. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AGER. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | AGER |
Name | advanced glycosylation end product-specific receptor |
Aliases | RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AGER. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | AGER |
Name | advanced glycosylation end product-specific receptor |
Aliases | RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of AGER expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | AGER |
Name | advanced glycosylation end product-specific receptor |
Aliases | RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between AGER and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | AGER |
Name | advanced glycosylation end product-specific receptor |
Aliases | RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ...... |
Chromosomal Location | 6p21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting AGER collected from DrugBank database. |
There is no record. |